Moderna will start clinical trials of its new vaccine against the South African strain of Covid-19

The pharmaceutical company has also announced additional investments to increase the global manufacturing capacity of its antigen.

Moderna's vaccine.

The Moderna pharmaceutical company has already completed the development of the vaccine candidate against the South African variant of Covid-19 and has sent the material to the competent authorities to start the clinical trial. The rapid updating of this antigen is due to the mRNA platform used, which allows greater flexibility when adapting it to deal with new strains of the virus.

In a statement, the company explains that it has designed strategies to deal with the variants of the coronavirus. Thus, it will evaluate the effects of the booster dose, a combination of the booster dose with the original vaccine, and a third dose of the vaccine that is already on the market.

“Moderna is committed to making all necessary updates to our vaccine until the pandemic is under control. We hope to show that booster doses, if needed, can be done at lower dose levels, which will allow us providemany more doses to the world population at the end of 2021 and 2022 if necessary”, explained Stéphane Bancel, executive director of the pharmaceutical company.

Production capacity

In addition to completing the development of its new vaccine against the South African strain, Moderna has also announced additional investments to increase global manufacturing capacity for its Covid-19 antigen.

Thus, the projected capacity for 2022 of the company has increased to 1,400 million doses. For 2021, Moderna is working to supply up to 1 billion.

In addition, the US drug agency has backed the company’s proposal to add more doses to each vial of the vaccine. The goal is to extract up to 15 doses from each vial.